Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.670
-0.001 (-0.16%)
At close: Oct 29, 2024, 4:00 PM
0.673
+0.003 (0.52%)
After-hours: Oct 29, 2024, 4:55 PM EDT
Bolt Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for BOLT stock have an average target of 1.25, with a low estimate of 1.00 and a high estimate of 1.50. The average target predicts an increase of 86.60% from the current stock price of 0.67.
Analyst Consensus: Hold
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for BOLT stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 15, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $3 → $1 | Buy → Hold | Downgrades | $3 → $1 | +49.28% | May 15, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2024 |
| Stifel | Stifel | Strong Buy → Hold Downgrades $6 → $1.5 | Strong Buy → Hold | Downgrades | $6 → $1.5 | +123.91% | May 15, 2024 |
Financial Forecast
Revenue This Year
9.16M
from 7.88M
Increased by 16.30%
Revenue Next Year
3.72M
from 9.16M
Decreased by -59.44%
EPS This Year
-1.55
from -1.83
EPS Next Year
-1.31
from -1.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.0M | 10.5M | 12.8M | ||
| Avg | 9.2M | 3.7M | 5.7M | ||
| Low | 7.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 40.0% | 14.5% | 243.4% | ||
| Avg | 16.3% | -59.4% | 54.7% | ||
| Low | -7.9% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.41 | -0.96 | -0.49 | ||
| Avg | -1.55 | -1.31 | -1.13 | ||
| Low | -1.63 | -2.11 | -2.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.